RespireRx Pharmaceuticals Inc. (RSPI)
Chart Events
Performance Outlook
| Previous Close | 0.0075 |
| Open | 0.0079 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0075 - 0.0088 |
| 52 Week Range | 0.0041 - 0.0450 |
| Volume | |
| Avg. Volume | 319,002 |
| Market Cap | 851,680 |
| Beta (5Y Monthly) | 0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Aug 12, 2020 - Aug 17, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RSPI
Related Research
- RESPIRERX PHARMACEUTICALS INCJAZZ: Raising target price to $167.00JAZZ PHARMACEUTICALS PLC has an Investment Rating of BUY; a target price of $167.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat2 days agoArgus Research
- GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces Recent RespireRx Presentation at 2022 GRI Virtual Conference presented by CureGRIN and GRIN Therapeutics.
Glen Rock, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that Dr. Arnold Lippa, Chief Scientific Officer, Executive Chairman of the Board and Interim President and Interim Chief Executive Officer was an invited speaker on April 23rd at the 2022 GRI Virtual Conf
- GlobeNewswire
RespireRx Pharmaceuticals Inc. Announces the Publication of a Review Article Highlighting the Potential Use of GABAkine Neuromodulators for the Treatment of Tinnitus
Glen Rock, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that scientists associated with the Company have published a manuscript that raises the hope of novel treatments for tinnitus, the perception of sound in the absence of external auditory stimulation. Tin
- Zacks Small Cap Research
Sleep Apnea—A Plague for America with More Help on the Way
By Brad Sorensen, CFA OTC:RSPI | NASDAQ:IXHL I had the pleasure of moderating a discussion on sleep apnea hosted by Force Family Office that featured the pioneer in the study of sleep science and inventor of the ubiquitous CPAP machine, Dr. Colin Sullivan. The founder and CEO of Sommetrics, Dr. Richard Rose, also joined and spoke about the science behind sleep apnea as well as introducing a new
